bluebird bio logo
bluebird bio BLUE

Quarterly report 2025-Q1
added 05-14-2025

report update icon

bluebird bio Cost of Revenue 2011-2025 | BLUE

Cost of Revenue is a financial metric that reflects all direct costs associated with the production of goods or the provision of services that directly led to revenue during the reporting period. It is the total amount of expenses incurred by the company to deliver its products or services, including both production costs and related expenses necessary for delivery or customer support.
What is included in the cost of revenue
Cost CategoryExamples
Production CostsMaterials, wages of production staff, depreciation of equipment
Service and SupportCustomer service, user support, technical assistance
Delivery and LogisticsPackaging, delivery of goods to customers
Hosting and InfrastructureServers, cloud platforms (especially for IT and SaaS companies)
Content and LicensesLicense purchases, production royalties (e.g., in streaming services)

Importance of the Metric
  • Helps to understand how costly the revenue-generating process is.
  • A high cost of revenue may indicate:
    Poor cost control
    Low operational efficiency
  • A low cost of revenue combined with high revenue indicates high profitability and business competitiveness.

Annual Cost of Revenue bluebird bio

2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
33.5 M 10.1 M - - 2.98 M 885 K 1.53 M - - - - - -

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
33.5 M 885 K 9.8 M

Quarterly Cost of Revenue bluebird bio

2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
12.2 M - 11.8 M 28.9 M 25.9 M - 9.13 M 6.7 M 5.51 M - - 1.74 M 8.31 M - 19.4 M 15.3 M 576 K - 1.32 M 1.55 M 1.02 M - 862 K 613 K 430 K - 29 K 21 K 17 K - 1.1 M 420 K - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Indicator range from quarterly reporting

Maximum Minimum Average
28.9 M 17 K 6.65 M

Cost of Revenue of other stocks in the Biotechnology industry

Issuer Cost of Revenue Price % 24h Market Cap Country
AbbVie AbbVie
ABBV
16.9 B $ 223.01 -0.99 % $ 395 B usaUSA
Aclaris Therapeutics Aclaris Therapeutics
ACRS
2.79 M $ 3.38 3.21 % $ 261 M usaUSA
Acasti Pharma Acasti Pharma
ACST
76 K - 4.01 % $ 150 M canadaCanada
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
3.52 M $ 212.3 5.5 % $ 5 B danmarkDanmark
BioVie BioVie
BIVI
312 K $ 1.54 -2.53 % $ 2.28 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
1.36 M - -0.23 % $ 916 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
421 K $ 1.33 -1.48 % $ 7.25 M chinaChina
AstraZeneca PLC AstraZeneca PLC
AZN
12.4 B $ 90.34 -1.28 % $ 96.9 B britainBritain
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
358 M $ 25.76 0.19 % $ 1.25 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
63.6 M $ 9.53 -1.19 % $ 140 M usaUSA
Aytu BioScience Aytu BioScience
AYTU
20.6 M $ 2.33 2.3 % $ 14.6 M usaUSA
Axon Enterprise Axon Enterprise
AXON
841 M $ 586.28 3.15 % $ 44.4 B usaUSA
Biogen Biogen
BIIB
2.31 B $ 173.03 -2.55 % $ 25.2 B usaUSA
BioNTech SE BioNTech SE
BNTX
2.91 B $ 95.9 0.17 % $ 27.2 B germanyGermany
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
91.7 M $ 11.55 8.86 % $ 747 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
4.64 M $ 15.32 5.73 % $ 1.01 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
70.7 M - 0.49 % $ 251 B cayman-islandsCayman-islands
Cerus Corporation Cerus Corporation
CERS
33.4 M $ 2.14 13.23 % $ 395 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
15.3 M - -24.86 % $ 820 K usaUSA
Berkeley Lights Berkeley Lights
BLI
24.8 M - -7.31 % $ 87 M usaUSA
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
BMY
14 B $ 51.05 -0.32 % $ 103 B usaUSA
ADiTx Therapeutics ADiTx Therapeutics
ADTX
627 K $ 2.36 -7.29 % $ 31.1 K usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
2.14 M $ 2.1 -4.34 % $ 5.32 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
159 M $ 1.42 6.77 % $ 134 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
200 K $ 28.33 0.5 % $ 1.82 M usaUSA
Advaxis Advaxis
ADXS
13 K - -9.65 % $ 45.9 M usaUSA
Baudax Bio Baudax Bio
BXRX
7.01 M - 0.59 % $ 63 K usaUSA